How does Glycerosome encapsulation compare to conventional hot water and alcohol extraction? A detailed comparison across bioavailability, compound spectrum, quality control, and cost-effectiveness.
| Category | Standard Extraction | ME-Glycerosorb™ (Glycerosome) |
|---|---|---|
| Bioavailability | 1x baseline — significant compound loss during GI transit | 5-10x enhanced — chitosan-stabilized vesicles protect compounds and improve absorption |
| Compound Spectrum | Partial — single-solvent extraction captures only water-soluble OR alcohol-soluble compounds | Full spectrum — dual water-alcohol solvent captures polysaccharides, terpenes, and all bioactive classes |
| GI Tract Protection | Minimal — bioactive compounds degrade during gastric transit | Chitosan coating provides positive charge for membrane adhesion and GI protection |
| Cell Absorption | Passive diffusion only — slow, inefficient compound uptake | Active charge-based adhesion to cell membranes — rapid, efficient compound delivery |
| Quality Control | Basic batch testing with variable encapsulation rates | Pharmaceutical-grade Tangential Flow Filtration (TFF) ensures consistent encapsulation |
| Batch Consistency | Significant variation between production batches | Standardized nano-vesicle size and encapsulation efficiency per batch |
| Cost per Unit | Lower initial cost per kilogram | Higher cost per kg, but dramatically lower cost per unit of absorbed bioactive compound |
| Applications | Powders, capsules, basic tinctures | Functional beverages, shots, liquid supplements, high-potency capsules, dairy products |
| Scientific Validation | Well-established but limited bioavailability data | Published research with Dr. Bartosz Zambron (IChO PAN) and Croda Pharma |
For premium supplement brands and functional food manufacturers, Glycerosome extraction delivers measurably superior results. While the per-kilogram cost is higher, the dramatically improved bioavailability means lower effective cost per unit of absorbed bioactive compound.
Standard extraction remains appropriate for basic applications where bioavailability is not the primary differentiator. For brands competing on efficacy and scientific credibility, Glycerosome technology provides a defensible competitive advantage.